Top

Published in:

Open Access 01-12-2024 | Acute Kidney Injury | Research

Evaluation of a new score associated with acute kidney injury in patients treated with cisplatin based EXTREME regimen

Authors: François Avry, Charles Roseau, Zoé Leguay, Sixtine Brabant, Alexandre Ganea, Elise Champeaux-Orange, Véronique Priou

Published in: BMC Cancer | Issue 1/2024

Abstract

Background

This study evaluates the association of diuresis and hydration through a new monitoring indicator called \({U}_{sen}\) and the risk of acute kidney injury in patients treated with cisplatin based-EXTREME regimen.

Methods

We retrospectively reviewed all the cycles of patients with recurrent and/or metastatic head and neck cancer who received cisplatin based-EXTREME regimen from June 2008 to July 2022. Hydration regimen, urine output and concomitant treatments data were collected on the day of cisplatin infusion and the following day of each course received.

Results

Of the 110 courses received by 46 patients, 38 (34.5%) results in AKI. No patient characteristics showed a significant difference between AKI (70%) and non-AKI (30%) group. In univariate analysis, dose reduction of cisplatin (odds ratio = 0.166 [0.04; 0.75], p = 0.01)) and \({U}_{sen}\) >8 (odds ratio = 0.316 [0.133; 0.755], p = 0.015) and cardiac treatments (odds ratio = 3.24 [1.26; 8.52], p = 0.02) were significantly associated with AKI risk. In multivariate analysis, cisplatin dose reduction (odds ratio = 0.129 [0.0241; 0.687], p = 0.016) and \({U}_{sen}\) >8 (odds ratio = 0.184 [0.0648; 0.523], p = 0.0015) were associated with a risk reduction of cisplatin-related AKI. Concomitant administration of cardiac treatments (odds ratio = 3.18 [1.1; 9.22], p = 0.033) showed an increased risk of cisplatin-related AKI.

Conclusion

The combination of diuresis and i.v. hydration through the \({U}_{sen}\) composite score was shown to be associated with cisplatin-induced AKI risk in patients treated with cisplatin based EXTREME regimen. It could be used as a practical indicator to trigger specific clinical management to limit the risk of cisplatin induced AKI.

Ferlay J. Cancer tomorrow. https://gco.iarc.fr/tomorrow/. Accessed 30 Aug 2022.

Aupérin A. Epidemiology of head and neck cancers: an update. Curr Opin Oncol. 2020;32(3):178–86. https://doi.org/10.1097/CCO.0000000000000629.CrossRefPubMed

McDermott JD, Bowles DW. Epidemiology of head and neck squamous cell carcinomas: impact on staging and prevention strategies. Curr Treat Options Oncol. 2019;20(5):43. https://doi.org/10.1007/s11864-019-0650-5.CrossRefPubMed

Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist. 2010;15(9):994–1001. https://doi.org/10.1634/theoncologist.2009-0289.CrossRefPubMedPubMedCentral

Cancer of the Oral Cavity and Pharynx - Cancer Stat Facts. SEER. https://seer.cancer.gov/statfacts/html/oralcav.html. Accessed 30 Aug 2022.

Sturgis EM, Miller RH. Second primary malignancies in the head and neck cancer patient. Ann Otol Rhinol Laryngol. 1995;104(12):946–54. https://doi.org/10.1177/000348949510401206.CrossRefPubMed

Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet Lond Engl. 2008;371(9625):1695–709. https://doi.org/10.1016/S0140-6736(08)60728-X.CrossRef

Pignon JP, le Maître A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14. https://doi.org/10.1016/j.radonc.2009.04.014.CrossRefPubMed

Muzaffar J, Bari S, Kirtane K, Chung CH. Recent advances and future directions in clinical management of head and neck squamous cell carcinoma. Cancers. 2021;13(2):338. https://doi.org/10.3390/cancers13020338.CrossRefPubMedPubMedCentral

10.

Head and Neck Cancers, Version 2.2020, NCCN cinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2020;18(8):873–898. https://doi.org/10.6004/jnccn.2020.0031. Accessed 1 Sept 2022.

11.

Zafereo ME, Hanasono MM, Rosenthal DI, et al. The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. Cancer. 2009;115(24):5723–33. https://doi.org/10.1002/cncr.24595.CrossRefPubMed

12.

Temam S, Pape E, Janot F, et al. Salvage surgery after failure of very accelerated radiotherapy in advanced head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2005;62(4):1078–83. https://doi.org/10.1016/j.ijrobp.2004.12.062.CrossRefPubMed

13.

Samra B, Tam E, Baseri B, Shapira I. Checkpoint inhibitors in head and neck cancer: current knowledge and perspectives. J Investig Med. 2018;66(7):1023–30. https://doi.org/10.1136/jim-2018-000743.CrossRefPubMed

14.

Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915–28. https://doi.org/10.1016/S0140-6736(19)32591-7.CrossRefPubMed

15.

Burtness B, Zhang Y, Harrington KJ, Rischin D. Further clinical interpretation and implications of KEYNOTE-048 findings – authors’ reply. Lancet. 2020;396(10248):379–80. https://doi.org/10.1016/S0140-6736(20)30900-4.CrossRefPubMed

16.

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer | NEJM. https://www.nejm.org/doi/full/10.1056/nejmoa0802656. Accessed 2 June 2022.

17.

Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol Off J Am Soc Clin Oncol. 1992;10(8):1245–51. https://doi.org/10.1200/JCO.1992.10.8.1245.CrossRef

18.

Saad AAA, Zhang F, Mohammed EAH, Wu X. Clinical aspects of drug-drug interaction and drug nephrotoxicity at renal organic Cation Transporters 2 (OCT2) and Multidrug and Toxin Exclusion 1, and 2-K (MATE1/MATE2-K). Biol Pharm Bull. 2022;45(4):382–93. https://doi.org/10.1248/bpb.b21-00916.CrossRefPubMed

19.

Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23(5):460–4. https://doi.org/10.1016/S0270-9295(03)00089-5.CrossRefPubMed

20.

Workeneh BT, Uppal NN, Jhaveri KD, Rondon-Berrios H. Hypomagnesemia in the cancer patient. Kidney 360. 2020;2(1):154–66. https://doi.org/10.34067/KID.0005622020.CrossRefPubMedPubMedCentral

21.

Perazella MA, Rosner MH. Drug-induced acute kidney injury. Clin J Am Soc Nephrol. 2022;17(8):1220–33. https://doi.org/10.2215/CJN.11290821.CrossRefPubMedPubMedCentral

22.

Duan Z, Cai G, Li J, Chen X. Cisplatin-induced renal toxicity in elderly people. Ther Adv Med Oncol. 2020;12:1758835920923430. https://doi.org/10.1177/1758835920923430.CrossRefPubMedPubMedCentral

23.

van der Vorst MJDL, Neefjes ECW, Toffoli EC, et al. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin. BMC Cancer. 2019;19:1066. https://doi.org/10.1186/s12885-019-6233-9.CrossRefPubMedPubMedCentral

24.

Jhaveri KD, Sakhiya V, Wanchoo R, Ross D, Fishbane S. Renal effects of novel anticancer targeted therapies: a review of the Food and Drug Administration Adverse Event Reporting System. Kidney Int. 2016;90(3):706–7. https://doi.org/10.1016/j.kint.2016.06.027.CrossRefPubMed

25.

Yamashiro K. Retrospective Investigation of factors influencing time-dependent changes in serum magnesium levels in patients receiving cetuximab. 2021.CrossRef

26.

Kidera Y, Kawakami H, Sakiyama T, et al. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS ONE. 2014;9(7):e101902. https://doi.org/10.1371/journal.pone.0101902.CrossRefPubMedPubMedCentral

27.

Lajer H, Kristensen M, Hansen HH, et al. Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol. 2005;56(5):535–42. https://doi.org/10.1007/s00280-005-1010-7.CrossRefPubMed

28.

Motwani SS, McMahon GM, Humphreys BD, Partridge AH, Waikar SS, Curhan GC. Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin. J Clin Oncol. 2018;36(7):682–8. https://doi.org/10.1200/JCO.2017.75.7161.CrossRefPubMedPubMedCentral

29.

Dierckes SJ, Ragsdale ME, Macik MR, Weddle KJ. Retrospective analysis of the incidence and severity of acute kidney injury (AKI) in patients with head and neck cancer receiving weekly cisplatin with radiotherapy (RAISe-AKI). J Oncol Pharm Pract: Official Publication of the International Society of Oncology Pharmacy. 2021;27(8)1923–28. https://journals.sagepub.com/doi/10.1177/1078155220978454?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed& . Accessed 7 Sept 2022.

30.

Kuhlmann MK, Burkhardt G, Köhler H. Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 1997;12(12):2478–80. https://doi.org/10.1093/ndt/12.12.2478.CrossRef

31.

Cisplatin 1mg/ml Injection BP - Summary of Product Characteristics (SmPC) - (emc). https://www.medicines.org.uk/emc/product/6960/smpc#gref. Accessed 10 Jan 2023.

32.

Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M, European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol. 2008;61(6):903–9. https://doi.org/10.1007/s00280-008-0711-0.CrossRefPubMed

33.

Réseau onco-Normand. Hydratation des patients sous Cisplatine: Proposition d’une harmonisation régionale. 2014. https://www.google.fr/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwiKkIG3woP6AhUK2xoKHYufAvQQFnoECAkQAQ&url=https%3A%2F%2Fonconormandie.fr%2Fwp-content%2Fuploads%2F2017%2F10%2FHydratation-des-patients-sous-cisplatine-SFP-Sept-Oct-2005-.pdf&usg=AOvVaw1hvxO51IEvKCGtiVWTjUGq.

34.

Duffy EA, Fitzgerald W, Boyle K, Rohatgi R. Nephrotoxicity: evidence in patients receiving cisplatin therapy. Clin J Oncol Nurs. 2018;22(2):175–83. https://doi.org/10.1188/18.CJON.175-183.CrossRefPubMed

35.

Crona DJ, Faso A, Nishijima TF, McGraw KA, Galsky MD, Milowsky MI. A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist. 2017;22(5):609–19. https://doi.org/10.1634/theoncologist.2016-0319.CrossRefPubMedPubMedCentral

36.

Etude nationale nutrition santé. consommations alimentaires- groupes d’aliments- adultes 18–74 ans. Santé publique France. 2007 2006. https://www.santepubliquefrance.fr/content/download/55949/file/alimentation-adultes-aliments-2.pdf.

37.

SPF. Etude de santé sur l’environnement, la biosurveillance, l’activité physique et la nutrition (Esteban), 2014–2016. Volet Nutrition. Chapitre Corpulence. https://www.santepubliquefrance.fr/determinants-de-sante/nutrition-et-activite-physique/etude-de-sante-sur-l-environnement-la-biosurveillance-l-activite-physique-et-la-nutrition-esteban-2014-2016.-volet-nutrition.-chapitre-corpulence. Accessed 20 Dec 2022.

38.

EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA). Scientific opinion on dietary reference values for water. EFSA J. 2010;8(3):1459. https://doi.org/10.2903/j.efsa.2010.1459.CrossRef

39.

Li Y, Zhu B, Song N, Shi Y, Fang Y, Ding X. Alcohol consumption and its association with chronic kidney disease: evidence from a 12-year China health and nutrition survey. Nutr Metab Cardiovasc Dis NMCD. 2022;32(6):1392–401. https://doi.org/10.1016/j.numecd.2022.02.012.CrossRefPubMed

40.

Oda H, Mizuno T, Ikejiri M, et al. Risk factors for cisplatin-induced acute kidney injury: a pilot study on the usefulness of genetic variants for predicting nephrotoxicity in clinical practice. Mol Clin Oncol. 2020;13(5):58. https://doi.org/10.3892/mco.2020.2127.CrossRefPubMedPubMedCentral

41.

Faig J, Haughton M, Taylor RC, et al. Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy. Am J Clin Oncol. 2018;41(5):432–40. https://doi.org/10.1097/COC.0000000000000301.CrossRefPubMedPubMedCentral

42.

Kimura T, Ozawa T, Hanai N, et al. Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer. J Otolaryngol Head Neck Surg J Oto-Rhino-Laryngol Chir Cervico-Faciale. 2018;47(1):10. https://doi.org/10.1186/s40463-018-0261-3.CrossRef

43.

Rachman A, Shatri H, Salamat R. Correlation between higher cumulative dose of cisplatin for concurrent chemoradiation and acute kidney disease incidence among nasopharyngeal carcinoma patients: a comparative study. Int J Gen Med. 2021;14:10527–39. https://doi.org/10.2147/IJGM.S343644.CrossRefPubMedPubMedCentral

44.

de Jongh FE, van Veen RN, Veltman SJ, et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer. 2003;88(8):1199–206. https://doi.org/10.1038/sj.bjc.6600884.CrossRefPubMedPubMedCentral

45.

Bhat ZY, Cadnapaphornchai P, Ginsburg K, et al. Understanding the risk factors and long-term consequences of cisplatin-associated acute kidney injury: an observational cohort study. PLoS One. 2015;10(11):e0142225. https://doi.org/10.1371/journal.pone.0142225.CrossRefPubMedPubMedCentral

46.

Tan SS, Van Gils CWM, Franken MG, Hakkaart-van Roijen L, Uyl-de Groot CA. The unit costs of inpatient hospital days, outpatient visits, and daycare treatments in the fields of oncology and hematology. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2010;13(6):712–9. https://doi.org/10.1111/j.1524-4733.2010.00740.x.CrossRef

47.

Nagai N, Ogata H. The renal clearance of unchanged cisplatin during furosemide and mannitol diuresis is dependent on glomerular filtration rate in rats. J Pharm Sci. 1996;85(7):720–4. https://doi.org/10.1021/js9505152.CrossRefPubMed

48.

Fukushima K, Okada A, Oe H, et al. Pharmacokinetic-pharmacodynamic analysis of cisplatin with hydration and Mannitol Diuresis: the contribution of urine cisplatin concentration to nephrotoxicity. Eur J Drug Metab Pharmacokinet. 2018;43(2):193–203. https://doi.org/10.1007/s13318-017-0436-8.CrossRefPubMed

49.

Pressoir M, Desné S, Berchery D, et al. Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer. 2010;102(6):966–71. https://doi.org/10.1038/sj.bjc.6605578.CrossRefPubMedPubMedCentral

50.

Jager-Wittenaar H, Dijkstra PU, Vissink A, van der Laan BFAM, van Oort RP, Roodenburg JLN. Critical weight loss in head and neck cancer–prevalence and risk factors at diagnosis: an explorative study. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2007;15(9):1045–50. https://doi.org/10.1007/s00520-006-0212-9.CrossRef

51.

Ivanov AI, Christodoulou J, Parkinson JA, et al. Cisplatin binding sites on human albumin*. J Biol Chem. 1998;273(24):14721–30. https://doi.org/10.1074/jbc.273.24.14721.CrossRefPubMed

52.

Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, Goel R. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol. 1997;40(4):293–308. https://doi.org/10.1007/s002800050661.CrossRefPubMed

53.

Koide H, Noda S, Okunuki Y, et al. Analysis of risk factors for high-dose cisplatin-induced renal impairment in head and neck cancer patients. In Vivo. 2022;36(5):2465–72. https://doi.org/10.21873/invivo.12982.CrossRefPubMedPubMedCentral

54.

Takeuchi K, Sogawa R, Tsuruhashi S, Motooka C, Kimura S, Shimanoe C. Antihypertensive drug combinations modify cisplatin-induced acute kidney injury. In Vivo. 2022;36(3):1391–6. https://doi.org/10.21873/invivo.12843.CrossRefPubMedPubMedCentral

55.

Galfetti E, Cerutti A, Ghielmini M, Zucca E, Wannesson L. Risk factors for renal toxicity after inpatient cisplatin administration. BMC Pharmacol Toxicol. 2020;21(1):19. https://doi.org/10.1186/s40360-020-0398-3.CrossRefPubMedPubMedCentral

56.

Miyoshi T, Uoi M, Omura F, Tsumagari K, Maesaki S, Yokota C. Risk factors for cisplatin-induced nephrotoxicity: a multicenter retrospective study. Oncology. 2021;99(2):105–13. https://doi.org/10.1159/000510384.CrossRefPubMed

57.

Ivanyuk A, Livio F, Biollaz J, Buclin T. Renal drug transporters and drug interactions. Clin Pharmacokinet. 2017;56(8):825–92. https://doi.org/10.1007/s40262-017-0506-8.CrossRefPubMed

Title: Evaluation of a new score associated with acute kidney injury in patients treated with cisplatin based EXTREME regimen
Authors: François Avry
Charles Roseau
Zoé Leguay
Sixtine Brabant
Alexandre Ganea
Elise Champeaux-Orange
Véronique Priou
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Acute Kidney Injury
Acute Kidney Injury
Cetuximab
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-12157-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Colonoscopy screening for colorectal cancer in Egypt: a nationwide cross-sectional study

A cost-benefit analysis of genetic screening test for breast cancer in Iran

Tenascin C as a novel zinc finger protein 750 target regulating the immunogenicity via DNA damage in lung squamous cell carcinoma

WNT3 promotes chemoresistance to 5-Fluorouracil in oral squamous cell carcinoma via activating the canonical β-catenin pathway

High expression of SRSF1 facilitates osteosarcoma progression and unveils its potential mechanisms

A systematic review and meta-analysis on mortality rate following total pelvic exenteration in cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer